P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
Maria-Victoria Mateos,
Nizar J Bahlis,
Andrew Spencer,
Rayan Kaedbey,
Paula Rodríguez-Otero,
Simon Harrison,
Chihunt Wong,
Grant Goodman,
Rin Nakamura,
Voleak Choeurng,
James Cooper,
Suzanne Trudel
Affiliations
Maria-Victoria Mateos
1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain
Nizar J Bahlis
2 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
Andrew Spencer
3 Alfred Health-Monash University, Melbourne, VIC, Australia
Rayan Kaedbey
4 Jewish General Hospital, McGill University, Montreal, QC, Canada
Paula Rodríguez-Otero
5 Clínica Universidad de Navarra, Pamplona, Spain
Simon Harrison
6 Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, VIC, Australia
Chihunt Wong
7 Genentech, Inc., South San Francisco, CA, United States
Grant Goodman
7 Genentech, Inc., South San Francisco, CA, United States
Rin Nakamura
7 Genentech, Inc., South San Francisco, CA, United States
Voleak Choeurng
7 Genentech, Inc., South San Francisco, CA, United States
James Cooper
7 Genentech, Inc., South San Francisco, CA, United States
Suzanne Trudel
8 Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
